KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Retained Earnings (2017 - 2025)

Bionano Genomics' Retained Earnings history spans 7 years, with the latest figure at -$711.7 million for Q3 2025.

  • For Q3 2025, Retained Earnings fell 5.73% year-over-year to -$711.7 million; the TTM value through Sep 2025 reached -$711.7 million, down 5.73%, while the annual FY2024 figure was -$693.2 million, 19.27% down from the prior year.
  • Retained Earnings for Q3 2025 was -$711.7 million at Bionano Genomics, down from -$703.2 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $14000.0 in Q1 2025 and bottomed at -$711.7 million in Q3 2025.
  • The 5-year median for Retained Earnings is -$348.7 million (2022), against an average of -$329.7 million.
  • The largest annual shift saw Retained Earnings plummeted 64596.66% in 2022 before it surged 187.5% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$539000.0 in 2021, then tumbled by 64596.66% to -$348.7 million in 2022, then plummeted by 66.67% to -$581.2 million in 2023, then decreased by 19.27% to -$693.2 million in 2024, then dropped by 2.67% to -$711.7 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Retained Earnings are -$711.7 million (Q3 2025), -$703.2 million (Q2 2025), and $14000.0 (Q1 2025).